India and Brazil are exploring new opportunities to expand bilateral pharmaceutical trade through enhanced regulatory cooperation and business engagement.

The India–Brazil Healthcare Business Gateway, organised by the Pharmaceuticals Export Promotion Council of India (Pharmexcil), brought together industry representatives and regulatory stakeholders to facilitate market access and strengthen trade ties. The initiative focused on supporting Indian pharmaceutical companies in navigating Brazil’s regulatory landscape and building partnerships with local healthcare players.

Brazil accounted for approximately 2.8 Percent of India’s total pharmaceutical exports in FY25, with exports exceeding USD 778.49 million. During April–January FY26, exports reached USD 740.33 million, reflecting steady growth and underscoring Brazil’s importance as an emerging market for Indian drugmakers.

The discussions highlighted opportunities in areas such as oncology, biosimilars, complex generics and hospital supplies, particularly for Indian micro, small and medium enterprises (MSMEs). Stakeholders emphasized the need to streamline regulatory pathways with Brazil’s health surveillance authority, ANVISA, to facilitate smoother product approvals and faster market entry.

Brazil’s expanding healthcare demand and focus on affordable medicines present significant growth potential for Indian pharmaceutical exporters. Strengthened regulatory dialogue and business collaboration are expected to further enhance trade volumes and create long-term partnerships between the two countries.

The initiative reflects broader efforts by India and Brazil to deepen economic engagement across strategic sectors, with pharmaceuticals identified as a key area for future growth.